Testing a new tissue engineering device for breast reconstruction after cancer surgery
Official title: First-in-human Study of MATTISSE® Tissue Engineering Chamber in Adult Female After Total Mastectomy for Breast Cancer in Immediate or Delayed 2-stage Tissue Expander Reconstruction or Conversion From Implant-based to Autologous Reconstruction
Run by Quanta Medical · NCT05460780 · Data updated 2026-11-12
This study is testing a new device to see if it can safely help women who need breast reconstruction after cancer surgery.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 50 (estimated) |
| Sponsor | Quanta Medical Industry-sponsored |
| Locations | 3 sites (Strasbourg, France and 2 other locations) |
| Status | Recruiting |
| Started | July 1, 2022 |
| Main results expected | July 31, 2027 |
| Study ends | December 31, 2028 |
| Registry record updated | March 20, 2025 |
| Trial ID | NCT05460780 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adult females over 18 years old who require autologous breast reconstruction after mastectomy for early-stage breast cancer.
✕Probably not a fit
Patients with advanced breast cancer requiring extensive oncological management or those who cannot undergo the specified surgical procedures may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the safety and clinical performance of the MATTISSE tissue engineering chamber in adult female patients undergoing breast reconstruction following mastectomy for cancer. It is a first-in-human, two-stage, single-arm, non-comparative study. The focus is on patients requiring autologous breast reconstruction, either immediately after mastectomy or as a conversion from implant-based reconstruction. The study aims to gather data on the device's effectiveness and safety profile in this specific patient population.
Why it matters
Potential benefit: If successful, this study could improve breast reconstruction outcomes for women recovering from cancer.
How similar studies have gone: While this is a first-in-human study, similar approaches in tissue engineering have shown promise in other contexts, suggesting potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Criteria related to pathology: * Female patient over 18 Years old * Patient who required autologous breast reconstruction: * Immediate unilateral reconstruction after total mastectomy for early-stage breast cancer * Breast reconstruction after unilateral preventive total mastectomy * or delayed unilateral reconstruction after total mastectomy for early-stage breast cancer with a tissue expander implantation * or conversion from implant-based to autologous reconstruction: Patient who had a breast implant during a previous reconstruction after total mastectomy for cancer, and who needs to change it. * For patient with active cancer: Patient with early-stage cancer (stage 0, I or II, with tumor size \< 50mm, without lymph-node involvement) needing oncological management that does not required radiotherapy after surgery on the breast area or on the flap donor site * Patient who required Nipple sparing (NSM) or Skin sparing mastectomy (SSM) with a unique surgical approach (same for mastectomy and implant) insertion; or implant removal for patient undergoing autologous conversion, or expender removal for patient undergoing differed reconstruction. * Autologous reconstruction using Lateral Intercostal Perforator (LICAP) flap or an intercostal thoracic artery perforation flap (LTAP) if oncological conditions do not allow for LICAP harvesting. * Patient medically fit for surgery without significant comorbidities * Breast cup-size less than D * Body mass index \>20 kg/m2 or patient for whom sufficient flap volume is expected according to surgeon's assessment * Adequate hematopoietic functions Criteria related to population: * Subjects who have given free, informed and written consent to participate in the study; * Patient able to answer questionnaires, able to communicate in the language of the study country; * Subjects affiliated to a social security schema or entitled to a social security scheme. Non-inclusion Criteria: Pathology related criteria: * Patient undergoing bilateral reconstruction * Patient undergoing bilateral preventive mastectomy * Patient undergoing simultaneous contralateral breast reduction, mastopexy, and augmentation * Previous history of radiotherapy on the breast area or on the flap donor site * Previous history of breast or axillary surgery that does not allow fat flap dissection * Presence of pacemaker or metallic prosthesis making patient unsuitable for MRI * Body mass index \>30 kg/m2 * Taking medication for weight loss at the time of inclusion visit * Presence of major medical conditions that may compromise patient's health and healing * Diabetes and a history of gestational diabetes * Active smoking * Microangiopathy, Vascular history and all systemic disease (systemic Raynaud's disease) * Patient with intertrigo or infection or alteration of the surgical site confirmed pre-operatively by clinical examination * Allergy to anesthetics or contrast media * Immunocompromised patient (HIV) or patient used immunosuppressants Population related criteria * Pregnant patient * or breastfeeding patient or woman who has nursed a child three months within inclusion * Participation in a clinical trial in the 3 months prior to the initial visit * Predicted unavailability during study. * Patient deprived of liberty or under guardianship. * Patient unable to give consent Medical device related criteria * Allergy to any of the components of the medical device. EXCLUSION CRITERIA * Positive or suspicious extemporaneous sentinel node biopsy * Non integrity of LICAP and LTAP vessels, showed by the pre-operative doppler * Patient not yet implanted with MATTISSE®, whose cancer stage will finally require radiotherapy treatment
Where it's running
-
CHU de Strasbourg
Strasbourg, France, France Recruiting -
Hospital of Lille
Lille, Nord, France Recruiting -
Institute of Clinical Oncology
Tbilisi, Georgia Recruiting
Study contacts
- Study coordinator: Pierre GUERRESCHI, Pr
- Email: clinic@lattice-medical.com
- Phone: 03.20.44.56.59
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Oncoliq blood test for early detection of breast cancer
This project will test whether a blood-based miRNA panel (the Oncoliq Test) can detect early breast cancer in adults 40–70 by comparing newly diagnosed, untreated patients with cancer-free controls.
-
Evaluating the safety of a new acellular dermal matrix in breast reconstruction
This study is testing a new type of material used in breast reconstruction surgery to see if it causes fewer complications for women with breast cancer compared to older materials.
-
Different skin care approaches to prevent skin reactions after mastectomy radiation
This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.
-
ESP Blocks to Help Pain After Breast Reconstruction with Autologous Flaps
This study tests whether erector spinae plane blocks can improve pain control after autologous free flap breast reconstruction in adults.
-
EndoBreast: Feasibility and outcomes of nipple-sparing endoscopic mastectomy with immediate reconstruction
This observational study tests whether endoscopic nipple-sparing mastectomy with immediate reconstruction is feasible and acceptable for women at risk or with breast cancer.
-
Access My Breast Cancer Care App
A breast cancer care app is being tested to see if it helps patients navigate care, feel more satisfied, and reduce in-person visits.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.